Form 4: United Therapeutics CFO James Edgemond Executes Stock Options and Sells Shares Under 10b5-1 Plan

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on August 19, 2024, according to a Form 4 filing with the SEC.

Summary

• On August 19, 2024, James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of the company's common stock.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
• Edgemond exercised options to acquire 3,266 shares at $120.26, then sold 3,266 shares at $329.02.
• He also exercised options to acquire 3,400 shares at $117.76, then sold 3,400 shares at $329.02.
• Additionally, Edgemond executed 'sell-to-cover' transactions, exercising 816 options at $120.26 and selling 571 shares at $329.02, holding the remaining 245 shares.
• He also exercised 850 options at $117.76 and sold 591 shares at $329.02, holding the remaining 259 shares.
• Following these transactions, Edgemond directly owns 2,082 shares of common stock.
• He also holds options for 45,734 shares at $120.26, 159,100 shares at $117.76, 44,918 shares at $120.26 and 158,250 shares at $117.76.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There's no inherent positive or negative implication.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 plan indicates that these trades were pre-planned and not based on any specific non-public information at the time of the transaction.

Comparison to Industry Standards

• Executive compensation packages often include stock options as incentives.
• The exercise and sale of shares by executives are common, especially under pre-arranged trading plans like Rule 10b5-1.
• Comparing the volume and frequency of these transactions to those of executives at similar-sized biotech companies (e.g., Vertex Pharmaceuticals, Regeneron) can provide context on whether these actions are typical or unusual.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• However, the use of a 10b5-1 plan suggests that the transactions were planned and should not be interpreted as a sudden change in management's outlook.

Key Dates